Logo.png
Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape 
March 24, 2021 21:10 ET | DelveInsight Business Research LLP
Los Angeles, USA, March 24, 2021 (GLOBE NEWSWIRE) -- Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape  Gonorrhea Pipeline report provides...
ezgif.com-gif-maker.png
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
September 30, 2019 01:00 ET | Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Summit Master_rgb_png.png
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
July 17, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...
Summit Master_rgb_png.png
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
June 20, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...
Summit Master_rgb_png.png
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
March 14, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
Summit Master_rgb_png.png
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
February 25, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
SpeeDx-SMALL--Master.png
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
December 06, 2018 03:30 ET | SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...
Summit Master_rgb_png.png
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
November 12, 2018 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Preclinical Data on New...
Summit Master_CMYK _ jpeg.jpg
Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
September 05, 2018 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea SMT-571 Designed to...
Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
July 10, 2018 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the “’Company’) Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Non-Dilutive Funding...